PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Amyloid

Drugs in development · updated 30 October 2026

Amyloid: drugs in development

As of 30 October 2026 there are 12 active clinical trials (recruiting or ongoing, phases I–III) on 9 drugs for amyloid. 5 are experimental, that is not yet approved in the United States.

12Active trials
5Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ACI-24.060I–II1NCT05462106
AV-1959RII1NCT07827768
GAL-101II1NCT06659549
LY4405094I2NCT07787182
LY4560736I1NCT07843459

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DonanemabKisunla®III3NCT07602582
LemborexantDayvigo®II1NCT06823752
LenalidomideRevlimid, lenalinomideII1NCT06177028
SuvorexantBelsomra®II1NCT04629547

Sorted by most advanced phase and number of active trials.

All 9 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D058225 “Plaque, Amyloid”.

ItalianoFrançaisDeutsch